Novartis Unveils $30B In Deals To Drive Strategic Overhaul
Novartis AG on Tuesday unveiled several transactions worth nearly $30 billion combined that will dramatically reshape its operations, including the $16 billion acquisition of rival GlaxoSmithKline PLC's cancer drugs, making it...To view the full article, register now.
Already a subscriber? Click here to view full article